Platform dedicated to sepsis diagnosis directly at the patient’s bedside. In 5 minutes, it quantifies a predictive biomarker of sepsis using innovative technologies based on nanofluidic principles.
The biomarker used with abioSCOPE® is Pancreatic Stone Protein (PSP), a protein produced by the pancreas, whose blood concentration increases in the very early stages of sepsis development. It allows identification of patients at risk of developing organ dysfunction related to infection with high sensitivity and specificity compared to traditional methods.
Assessing PSP values with abioSCOPE® enables correct and early initiation of antibiotic therapy.
